Search
인용 및 참조 문헌 (2)
Invitrogen™
ViraPower™ HiPerform™ T-REx™ Gateway™ Expression System
The ViraPower™ HiPerform™ T-REx™ Gateway™ Expression System includes all the components needed to generate lentivirus, including vector kit, 293FT cell자세히 알아보기
| 카탈로그 번호 | 수량 |
|---|---|
| A11141 | 20 Reactions |
카탈로그 번호 A11141
제품 가격(KRW)
-
수량:
20 Reactions
The ViraPower™ HiPerform™ T-REx™ Gateway™ Expression System includes all the components needed to generate lentivirus, including vector kit, 293FT cell line, and the support kit. This kit combines Invitrogen's ViraPower™ HiPerform™ Lentiviral, T-REx™ and Gateway™ technologies to facilitate easy recombination-based cloning and lentiviral-based, regulated (Tetracycline-inducible), high-level expression of a target gene in dividing and non-dividing mammalian cells. The pLenti6.3/ TO/V5-DEST vector is equipped with two key genetic elements, making it a HiPerform™ vector: the Woodchuck Posttranscriptional Regulatory Element (WPRE) and the central Polypurine Tract (cPPT) sequence from the HIV-1 integrase gene to produce at least 4-fold increase in protein expression compared to vectors lacking these elements.
Advantages
- Generates replication-incompetent lentivirus for transducing dividing and non-dividing mammalian cells
- Easy recombination-based cloning using Gateway™ technology
- Stable, long-term, tetracycline-regulated expression
- Enhanced protein expression, up to 4-fold or greater, compared to traditional lentiviral expression systems
Key Features
- WPRE (Woodchuck Posttranscriptional Regulatory Element) from the woodchuck hepatitis virus, increases transgene expression and cPPT (central Polypurine Tract) from the HIV-1 integrase gene, increases the copy number of lentivirus integrating into the host genome, thus increasing viral titer. WPRE and cPPT together produce at least a four-fold increase in protein expression in most cell types, compared to other vectors that do not contain these elements.
- Hybrid promoter consisting of the human cytomegalovirus (CMV) promoter and two tetracycline operator 2 (TetO2) sites for high-level, regulated expression of the target gene
- Blasticidin selection marker for stable selection under control of SV40 promoter
Kit includes
- ViraPower™ HiPerform™ T-Rex™ Gateway™ Vector Kit (Cat. No. A11144)
- ViraPower™ Bsd Lentiviral Support Kit (K497000)
- 293FT Cell Line (R70007)
- Gateway™ LR Clonase™ II Plus Enzyme Mix (12538120)
- One Shot™ Stbl3™ Chemically Competent E. coli (C737303)
- Geneticin™ (10131035)
- pENTR™ Gus positive control plasmid
For Research Use Only. Not for use in diagnostic procedures.
사양
항생제 내성 박테리아Ampicillin (AmpR), Blasticidin (BsdR)
클로닝 방법Gateway
구성 또는 유도성 시스템Inducible
배달 유형Lentiviral
용도(애플리케이션)Protein Expression
용도(장비)Gateway™, HiPerform™, T-REx™, ViraPower™
Gateway 효소LR Clonase™ II Plus, LR Clonase™ II
유도제Doxycycline, Tetracycline
주요 기능Viral Expression
반응 수20 Reactions
PCR 효소Proof-Reading Polymerase
제품라인Gateway, HiPerform, T-REx, ViraPower
제품 유형Mammalian Expression system
단백질 태그V5 Epitope Tag
수량20 Reactions
복제 개시점pUC Origin
선택 제제(진핵)Blasticidin
선택 마커 진핵BsdR
선택 마커 프로모터PGK Promoter
특이 요소WPRE, cPPT
셀 유형293-FT
형식Kit
프로모터CMV/TO
VectorpLenti
Unit SizeEach
구성 및 보관
ViraPower™ HiPerform™ T-Rex™ Gateway™ Vector Kit (Cat. No. A11144)
• pLenti6.3/TO/V5-DEST vector (40 μL of vector at 150 ng/μL in TE Buffer, pH 8.0), 6 μg
• pLenti3.3/TR vector (40 μL of vector at 0.5 μg/μL in TE Buffer, pH 8.0), 20 μg
• pLenti6.3/TO/V5-GW/lacZ plasmid (20 μL of plasmid at 0.5 μg/μL in TE Buffer, pH 8.0), 10 μg
• Tetracycline (10 mg/mL in water), 1 mL. Store at -20°C, protect from light.
Store at -20°C unless otherwise noted
ViraPower™ Bsd Lentiviral Support Kit (Cat. No. K497000)
• ViraPower™ Lentiviral Packaging Mix (Contains 195 μL of a mixture of pLP1, pLP2, and pLP/VSVG plasmids, at 1 μg/μL in TE Buffer, pH 8.0), 195 μg. Store at -20°C.
• Lipofectamine™ 2000 (Cat. No. 11668027), 0.75 mL. Store at 4°C (Do not freeze)
• Blasticidin powder (Cat. No. R21001), 50 mg. Store at -20°C.
293FT Cell Line (Cat. No. R70007)
• 3 x 106 frozen cells in 1 mL of Freezing Medium, 1 vial. Store in liquid nitrogen
Gateway™ LR Clonase™ II Plus Enzyme Mix (Cat. No. 12538120)
• Gateway™ LR Clonase™ II Plus Enzyme Mix, 40 μL. Store -20°C for up to 6 months, -80°C for long term storage.
• Proteinase K Solution (2 ug/mL), 40 μL
One Shot™ Stbl3™ Chemically Competent E. coli (Cat. No. C737303)
• Stbl3™ Cells, 6 mL of S.O.C. Medium, 21 x 50 μL. Store at -80°C.
Geneticin™ (Cat. No. 10131035)
• Geneticin™ solution (50 mg/mL), 20 mL, store at 4°C or -20°C
• pENTR™ Gus positive control plasmid, store at -20°C
pUC19 control DNA, (10 pg/μL), 50 μL
자주 묻는 질문(FAQ)
Can I perform the single-step protocol for the BP/LR Clonase reaction using BP Clonase enzyme and LR Clonase enzyme instead of BP Clonase II enzyme and LR Clonase II enzyme?
Do you have a recommended single-step protocol for BP/LR recombination?
How can I move my gene of interest from a Gateway-adapted expression clone to a new Destination vector as I have lost the entry clone?
Can I purchase the 5X LR Clonase buffer or 5X BP Clonase buffer separately?
Do you offer Gateway vectors for expression in plants?
인용 및 참조 문헌 (2)
인용 및 참조 문헌
Abstract
Functional constraints of nuclear-mitochondrial DNA interactions in xenomitochondrial rodent cell lines.
Journal:J Biol Chem
PubMed ID:10908562
'The co-evolution of nuclear and mitochondrial genomes in vertebrates led to more than 100 specific interactions that are crucial for an optimized ATP generation. These interactions have been examined by introducing rat mtDNA into mouse cells devoid of mitochondrial DNA (mtDNA). When mtDNA-less cells derived from the common mouse (Mus
Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome.
Journal:Biochim Biophys Acta
PubMed ID:9540845
Although much progress has been made in identifying genetic defects associated with mitochondrial diseases, the protein expression patterns of most disorders are poorly understood. Here we use immunochemical techniques to describe subunit expression patterns of respiratory chain enzyme complexes II (succinate dehydrogenase: SD) and IV (cytochrome c oxidase: COX) in